Advertisement

Expert Point of View: Stephanie Lee, MD, MPH


Advertisement
Get Permission

ASH President Stephanie Lee, MD, MPH, Associate Director of the Clinical Research Division of Fred Hutchinson Cancer Research Center and Professor at the University of Washington, Seattle, congratulated the investigators on this extensive effort to collect real-world data to inform clinical practice on COVID-19 in patients with hematologic cancers.

Stephanie Lee, MD, MPH

Stephanie Lee, MD, MPH

“This study is an example of trying to harness real-world information until we have more controlled studies. The ASH Research Collaborative Data Hub collected real-world data on people with lab-confirmed COVID-19 infections and hematologic cancers from 74 sites. These people have heterogeneous diseases. The overall mortality rate was 28% among people with hematologic malignancies, and it was even higher if the patient’s pre-COVID prognosis was less than 12 months or if patients had advanced disease,” said Dr. Lee. 

DISCLOSURE: Dr. Lee has received clinical trial research funding from Amgen, AstraZeneca, Incyte, Kadmon, Novartis, Pfizer, Syndax, and Takeda and has served as a consultant to Incyte.


Related Articles

ASH Registry: Treasure Trove of Data on COVID-19 and Hematologic Malignancies

The ASH Research Collaborative COVID-19 Registry for Hematology provides up-to-date information on outcomes and the course of illness for a group of patients with hematologic malignancies and COVID-19.1 In general, registry data showed that hematologic malignancies increase the risk of severity of...

Advertisement

Advertisement



Advertisement